Publications by authors named "Jin-Shi Lv"
Article Synopsis
- A phase 3 trial (CHOICE-01) showed that combining toripalimab with chemotherapy significantly improves progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC).
- The final analysis revealed a median overall survival (OS) of 23.8 months for the toripalimab group compared to 17.0 months for the control group, particularly benefiting non-squamous patients.
- The study also emphasized the role of circulating tumor DNA (ctDNA) and tissue-based sequencing in identifying biomarkers that predict treatment efficacy, suggesting continuous ctDNA monitoring could enhance personalized treatment strategies.
Article Synopsis
- Research seeks to improve chemotherapy and PD-1 inhibitors for advanced non-small-cell lung cancer (NSCLC) by analyzing circulating tumor DNA (ctDNA) from 460 patients in the CHOICE-01 study.
- Key predictive markers such as ctDNA status, tumor mutational burden, and chromosomal instability were identified to tailor treatment strategies for better patient outcomes.
- An integrated ctDNA-based stratification system, called blood-based genomic immune subtypes (bGIS), offers a new way to personalize therapies and monitor treatment responses in advanced NSCLC patients.
Article Synopsis
- * A consensus among 147 experts revealed that a significant majority (97.74%) support rechallenging; while nearly half (48.87%) favor using the original drug, others prefer a different one.
- * Factors like previous performance status, PD-1 expression, and patient age are important in deciding on rechallenge, especially after experienced progression or metastasis.
Article Synopsis
- Immune checkpoint inhibitors have transformed treatment for non-small cell lung cancer (NSCLC), but secondary resistance to immunotherapy remains a significant challenge for many initial responders.
- A lack of clear definitions and consistent criteria in clinical trials complicates efforts to understand and address this resistance.
- An expert panel has proposed a comprehensive definition of secondary resistance to immunotherapy in NSCLC, aiming to improve clinical trial designs and future research discussions.
Background: The gut microbiota plays a crucial role in regulating host metabolism and producing uremic toxins in patients with end-stage renal disease (ESRD). Our objective is to advance toward a holistic understanding of the gut ecosystem and its functional capacity in such patients, which is still lacking.
Results: Herein, we explore the gut microbiome of 378 hemodialytic ESRD patients and 290 healthy volunteers from two independent cohorts via deep metagenomic sequencing and metagenome-assembled-genome-based characterization of their feces.
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that various panels showing the western blotting data in Figs. 1D, 3A, 6A and C, 9B and 10A, the Transwell migration and invasion assays in Fig. 10C, and the H&E staining images from the lung portrayed in Fig.
View Article and Find Full Text PDFBackground: Crescent formation indicates severe glomerular pathology, and hypothyroidism usually predicts poor prognosis for severe diseases. However, the relationship between thyroid function and the progression of chronic kidney disease (CKD) is unclear. This study analysed the prognostic predictive value of the serum free triiodothyronine (FT3) to free thyroxine (FT4) ratio and its correlation with renal function in patients with CKD with crescent formation.
View Article and Find Full Text PDFArticle Synopsis
- The CHOICE-01 study evaluated the effectiveness and safety of toripalimab combined with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).
- A total of 465 patients were enrolled, with the toripalimab group showing a median progression-free survival (PFS) of 8.4 months compared to 5.6 months in the placebo group, and a better overall survival (OS) at interim analysis.
- The study found that patients with a high tumor mutational burden and specific mutations had significantly improved outcomes with toripalimab, while adverse events were similar between both treatment groups, indicating a manageable safety profile.
Lung cancer continues to be an enormous burden on current health care systems throughout the world, with more than a million deaths every year. Previous studies have shown that interleukin-22 (IL-22) promotes survival and resistance to chemotherapy in human lung cancer cells. However, the association of IL-22 expression with recurrence of lung cancer is still unclear.
View Article and Find Full Text PDFTripartite motif 16 (TRIM16), a member of the RING B-box coiled-coil (RBCC)/tripartite totif (TRIM) protein family, has been demonstrated to have significant effects on tumor migration by previous studies, but its specific contribution to hepatocellular carcinoma (HCC) is currently unknown. The aim of this study was to evaluate the prognostic value of TRIM16 and investigate its functional roles in HCC. The expression of TRIM16 in HCC patient samples were examined using qRT-PCR and western blotting.
View Article and Find Full Text PDFHepatocellular carcinoma (HCC) is a common malignant tumor that severely threatens human health. The poor prognosis of HCC is mainly attributed to intrahepatic and extrahepatic metastases. HOXD9 proteins belong to a superfamily that regulates the development and control of many cellular processes, including proliferation, apoptosis, cell shape, and cell migration.
View Article and Find Full Text PDFObjectives: MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression and mediate diverse physiological processes. In this study, we investigated functions of miRNA miR-34c-3p in non-small cell lung cancer (NSCLC).
Materials And Methods: miR-34c-3p expression was evaluated by qPCR.